Authors: Tilici DM, Costinescu RM, Paun DL, Paun SC, Guja C.
Abstract Summary
Oral semaglutide shows promise for managing metabolic syndrome in patients with both type 2 diabetes and hypothyroidism. In a 6-month study of 51 patients, treatment significantly improved HbA1c, BMI, blood pressure, and lipid profiles. These findings suggest semaglutide may benefit this high-risk population, though larger prospective trials are needed to confirm results.
Why Brain? ๐ง
Oral semaglutide improved HbA1c, BMI, blood pressure, and lipids in hypothyroid-T2DM patients, suggesting benefit in this high-risk, understudied metabolic syndrome population.
Study Limitations:
Single-center retrospective cohort study
Small sample size of 51 adult patients
Observational study design
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
